BABeau M. Ances

Beau M. Ances

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Beau M. Ances has a total of 919 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Investigation of the Role of APOE in Down Syndrome Alzheimer’s Disease

    by Julie K. Wisch, Omar Abdelmoity, Lucía Maure-Blesa, James T. Kennedy, Maria Carmona Iragui, Annie Cohen, Íñigo Rodríguez-Baz, Melissa Petersen, Javier Arranz, Benjamin L. Handen, et al.

    Background: The Apolipoprotein E (APOE) ε4 allele increases the risk of Alzheimer's disease (AD), while the APOEε2 allele reduces risk. However, the effect of APOE haplotype and biological sex on AD in Down syndrome (DS) is unclear. Prior work has been limited by sample size, but here we aggregate the two largest APOE-genotyped cohorts of individuals with DS to date. Methods: We examined the impact of APOE genotype on AD biomarkers and cognitive performance in 1,212 individuals with DS. All participants underwent APOE testing and clinical evaluations. Subsets also completed assessments for amyloid (amyloid PET, CSF Aβ42/40), tau phosphorylation (plasma pTau217), neuroinflammation (plasma glial fibrillary acidic protein [GFAP]), neurodegeneration (plasma neurofilament light [NfL] and structural MRI), and episodic memory (modified Cued Recall Test [mCRT]). Results: APOEε2 was protective, associated with lower amyloid PET uptake and delayed cognitive impairment. In contrast, APOEε4 was associated with lower CSF Aβ42/Aβ40, worse mCRT performance, and earlier cognitive impairment. APOEε4 effects may be more pronounced in females. Conclusion: The APOE allele influences AD pathology and symptom onset in DS. Clinical trials, especially anti-amyloid therapies, should consider APOE status for intervention timing.

  • Open Access

    Structural brain indicators of cognitive performance in middle and late adulthood: The Human Connectome Project in Aging/Aging Adult Brain Connectome cohort

    by Yue Hong, Christa Michel, Gabriele Maria Gassner, Yiwen Zhang, Courtney Accorsi, Beau M. Ances, Lauren M. Antonucci, Steven E. Arnold, Ganesh M. Babulal, Susan Y. Bookheimer, et al.

  • Tau pathology and depression interact to accelerate driving decline in cognitively normal older adults

    by Yiqi Zhu, David C. Brown, Chen Chen, Ramkrishna K. Singh, Semere Bekena, Beau M. Ances, Eric J. Lenze, David B. Carr, Jean-Francios Trani, Ganesh M. Babulal

    Driving is a complex task that can be compromised by mood disorders and neurodegenerative conditions. Major depressive disorder (MDD) and Alzheimer’s disease (AD) increase in prevalence with older age. Preclinical AD, identified through protein biomarkers, is strongly associated with an increased risk of developing AD. This study tracked the daily driving behaviors of older adults over an average period of 54 months and found participants with MDD and Positron Emission Tomography (PET) biomarker tau had a faster increase in risky driving behaviors, such as hard braking, and a slower decline in randomness of driving patterns, compared to healthy controls. Notably, participants with MDD were more likely to exhibit PET tau positivity than PET amyloid positivity, suggesting a potential interaction between MDD and tau pathology. These findings highlight the importance of monitoring older drivers for emerging functional vulnerability associated with mood disorders and neurodegeneration at an early stage.

  • Open Access

    The Interactive Role of APOE and Sex in Down Syndrome Alzheimer’s Disease

    by Omar Abdelmoity, Julie K. Wisch, Lucía Maure-Blesa, James T. Kennedy, Maria Carmona Iragui, Annie Cohen, Íñigo Rodríguez-Baz, Melissa Petersen, Javier Arranz, Benjamin L. Handen, et al.

    Background: The Apolipoprotein E (APOE) ε4 allele increases the risk of Alzheimer's disease (AD), while the APOEε2 allele reduces risk, particularly in females in the neurotypical population. However, the effect of APOE haplotype and sex on AD in Down syndrome (DS) is unclear. Prior work has been limited by sample size, but here we aggregate the two largest APOE-genotyped cohorts of individuals with DS to date. Methods: We examined the impact of APOE genotype on AD biomarkers and cognitive performance in 1,212 individuals with DS. All participants underwent APOE testing and clinical evaluations. Subsets also completed assessments for amyloid (amyloid PET, CSF Aβ42/40, plasma pTau217), neuroinflammation (plasma glial fibrillary acidic protein [GFAP]), neurodegeneration (plasma neurofilament light [NfL] and structural MRI), and cognition (modified Cued Recall Test [mCRT]). Results: APOEε2 was protective, associated with lower amyloid PET uptake and delayed cognitive impairment. In contrast, APOEε4 was associated with lower CSF Aβ42/Aβ40, worse mCRT performance, and earlier cognitive impairment. These effects were more pronounced in females. Conclusion: APOE allele and biological sex interact to influence AD pathology and symptom onset in DS. Clinical trials, especially anti-amyloid therapies, should consider APOE status for intervention timing.Funding: Data collection and sharing for this project was supported by the ABC-DS (U01AG051406, U01AG051412, and U19 AG068054-04), funded by the National Institute on Aging and the Eunice Kennedy Shriver National Institute of Child Health and Human Development. JKW receives support from the NIH (KL2TR002346). Declaration of Interest: JF reports grants from the Fondo de Investigaciones Sanitario, Carlos III Health Institute (INT21/00073, PI20/01473 and PI23/01786 to JF) and the Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED) Program 1, jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, Una manera de hacer Europa. This work was also supported by the National Institutes of Health grants (1R01AG056850-01A1; R21AG056974, R01AG061566, 1R01AG081394-01 and 1R61AG066543-01 to JF), the Department de Salut de la Generalitat de Catalunya (SLT006/17/00119 to JF), Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP-DOW-2020-151). It was also supported by Horizon 2020 - Research and Innovation Framework Programme from the European Union (H2020-SC1- BHC-2018-2020 to JF). DA acknowledges support from Institute of Health Carlos III (ISCIII), Spain (PI18/00435, PI22/00611, PI25/00422, INT19/00016, INT23/00048) jointly funded by Fondo Europeo de Desarrollo Regional, Unión Europea, “Una manera de hacer Europa”, and by the Department of Health Generalitat de Catalunya PERIS program (SLT006/17/125, SLT042/25/000034). He also received support for Research Groups funding from the Department of Research and Universities from the Generalitat de Catalunya (2021 SGR 00979). AB acknowledges support from Instituto de Salud Carlos III and co-funded by the European Union through the Miguel Servet grant (CP20/00038) and Fondo de Investigaciones Sanitario (PI22/00307), the Alzheimer's Association (AARG-22-923680), and the Ajuntament de Barcelona, in collaboration with Fundació La Caixa (23S06157-001). LDHS acknowledges support from Instituto de Salud Carlos III through the Miguel Servet grant “CP24/00112” co- funded by the European Union, and the the Jérôme Lejeune Foundation (2326 - GRT-2024A). María Carmona-Iragui acknowledges support from Instituto de Salud Carlos III (ISCIII) (PI18/00335, PI22/00758, ICI23/00032); Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas CIBERNED Program 1, partly jointly funded by Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, Una Manera de Hacer Europa; Alzheimer's Association (AARG‐22‐973966); the Global Brain Health Institute (GBHI_ALZ‐18‐543740); the Jérôme Lejeune Foundation (#1913 cycle 2019B; #2425 cycle 2024B). MRA was supported by the Alzheimer’s Association Research Fellowship to Promote Diversity (AARF-D) Program (AARFD-21-852492) from 2022 until 2025. LVA is supported by the Sara Borrell postdoctoral fellowship from Institute of Health Carlos III (ISCIII), Spain (CD23/00235). BLH has received research funding from Roche and Autism Speaks; receives royalties from Oxford University Press for book publications; and is the chair of the data safety and monitoring board for the Department of Defense-funded study, “Comparative Effectiveness of EIBI and MABA”. BTC receives research funding from the National Institutes of Health. EH receives research funding from the National Institutes of Health and the BrightFocus Foundation. FL is supported by grants from the National Institute on Aging. HDR has received funding from the National Institutes of Health and is on the scientific advisory committee for the Hereditary Disease Foundation. JHL has received research funding from the National Institutes of Health and the National Institute on Aging. BMA receives research funding from the National Institutes of Health and has a patent (“Markers of Neurotoxicity in CAR T patients”). MSR has received consulting fees from AC Immune and Ionis, Alzheon, Alnylam, Biohaven, Embic, Positrigo and Prescient Imaging. He has received research support from the National Institutes of Health, Eisai and Lilly.. All other authors declare no competing interests. Lucia Maure-Blesa was supported by Instituto de Salud Carlos III through the Río Hortega Fellowship “CM23/00291” and co-funded by the European Union. SG acknowledges support from Institute of Health Carlos III (ISCIII), Spain (PI20/00836) jointly funded by Fondo Europeo de Desarrollo Regional, Unión...

  • Cross‐Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease

    by Omar Abdelmoity, Julie K. Wisch, James T. Kennedy, Manu Goyal, Andrei Vlassenko, Shaney Flores, Benjamin L. Handen, Elizabeth Head, David Keator, Michael S. Rafii, et al.

    Objectives: Directly compare the brain glucose patterns seen with [F‐18] fluorodeoxyglucose (FDG) positron emission tomography (PET) between 2 genetically determined forms of Alzheimer's disease: Down syndrome (DS) and autosomal dominant Alzheimer's disease (ADAD). Methods: Cross‐sectional analyses of FDG were performed in individuals with DS (n = 76) from the Alzheimer Biomarker Consortium‐Down Syndrome (ABC‐DS), ADAD (n = 297), and neurotypical familial controls (n = 188) from the Dominantly Inherited Alzheimer Network (DIAN). Within‐group linear regression models and generalized additive models were performed for select regional FDG uptake measures (isthmus cingulate and inferior parietal, precuneus, middle temporal gyrus, and precentral gyrus). Age, sex, apolipoprotein (APOE) ε4 carrier status, and cortical amyloid burden were included within these analyses. Results: Even 20 years before expected onset of clinical symptoms, FDG uptake was lower for DS compared to neurotypical familial controls ( p < 0.01). ADAD baseline FDG was similar to neurotypical familial controls until 7 years before expected symptom onset. Both symptomatic individuals with DS and ADAD had lower FDG compared to neurotypical familial controls ( p < 0.01). A higher amyloid burden was associated with lower FDG for both genetic forms, with similar rates of decline in FDG uptake for DS and ADAD who were amyloid positive. Interpretation: Brain glucose metabolism is substantially lower for people with DS, even in individuals who are cognitively stable. The patterns of FDG decline are distinct in these 2 genetically determined forms of AD. The diagnostic utility of FDG‐PET is specific to the genetic form of AD. ANN NEUROL 2025;98:1237–1248


  • Hearing loss, plasma neurodegenerative biomarkers, and cognitive function: Independent and additive effects

    by Semere Bekena, Ramkrishna K Singh, Yiqi Zhu, Carlos Cruchaga, Steven E Arnold, Beau M Ances, Ganesh M Babulal

    Background: Hearing loss is one of the most prominent modifiable risk factors for dementia, accounting for one of the largest population-attributable risk among midlife exposures according to the Lancet Commission on Dementia. Plasma biomarkers such as neurofilament light (NfL), glial fibrillary acidic protein (GFAP), and phosphorylated tau-217 (Ptau 217 ) have emerged as promising indicators of neurodegeneration and Alzheimer's disease (AD) pathology. Objective: To evaluate whether hearing loss and plasma biomarker concentrations are independently associated with cognitive function in aging adults, and to examine if these associations vary by age group. Methods: This cross-sectional study used data from 373 participants in the Aging Adult Brain Connectome (AABC) study. Hearing was assessed using the NIH Toolbox Words-in-Noise test, and cognitive function was measured by a Preclinical Alzheimer's Cognitive Composite (PACC). Plasma biomarkers included NfL, GFAP, total tau (tTau), and Ptau 217 . General linear models tested associations with cognition, adjusting for demographic, genetic, and cardiometabolic covariates. Interaction terms assessed modification by age and hearing. Results: Hearing loss was independently associated with lower PACC scores (β = −0.03, p < 0.001), after adjusting for covariates. Higher levels of NfL, GFAP, and Ptau 217 were each associated with worse cognition. Age significantly moderated these associations, with stronger biomarker–cognition links observed in adults aged 65 and older. No significant interactions were observed between hearing loss and plasma biomarkers. Conclusions: Hearing loss and plasma biomarkers reflect distinct, additive pathways of cognitive decline. These findings support integrated dementia risk models and highlight the potential of age- and biomarker-informed cognitive monitoring.


  • Open Access

    Early Syndecan-4 Upregulation Predicts Cognitive and Pathological Trajectories in Alzheimer Disease

    by Rawan Tarawneh, Krista L. Moulder, Danai G. Topouza, Amrita Kar, Heng (Tony) Qian, Vernon S. Pankratz, Jigyasha Timsina, Erin E. Franklin, Suzanne E. Schindler, Richard J. Perrin, et al.

    Objective: Brain endothelial dysfunction is an early pathological feature of Alzheimer disease (AD). Syndecan-4 (SDC4) is a heparan sulfate proteoglycan which is an important component of the brain endothelial glycocalyx. In this study, we investigate SDC4 associations with amyloid and tau pathologies and cognitive impairment in a large longitudinal cohort of AD, including preclinical AD, and controls. Methods: The study included n =1,041 ( n =802 cognitively unimpaired and n =239 cognitively impaired) participants. Biological classification using the National Institute of Aging-Alzheimer’s Association “ATN” framework was performed in all participants. Cognitive assessments included the Clinical Dementia Rating ® -sum of boxes and the Knight-Preclinical Alzheimer’s Cognitive Composite which includes episodic memory, language, and executive function scores. Cerebrospinal fluid (CSF) total tau, p-tau181, and Aβ42/Aβ40 levels were measured using Lumipulse assays. CSF measures of SDC4 and established AD biomarkers were obtained using the Explore HT Olink Proteomics platform. Amyloid-PET ( n =719) and tau-PET ( n =302) scans were performed in subsets of participants. Partial correlations and linear mixed models, respectively, examined cross-sectional and longitudinal associations of CSF SDC4 levels with amyloid-PET and tau-PET burden and cognition adjusting for co-variates. CSF biomarker trajectories across the course of AD progression were estimated using pseudo-time models. Results: CSF SDC4 levels were elevated in AD, including the earliest preclinical stages, compared to controls and were closely associated with CSF and imaging biomarkers of amyloid and tau, and CSF biomarkers of neuronal and synaptic injury, astrocytic reactivity and microglial dysregulation. Higher CSF SDC4 levels correlated with higher global and regional amyloid-PET and tau-PET burden and worse baseline cognition. Higher baseline CSF SDC4 levels predicted more rapid progression of brain amyloid and tau, and faster decline in global cognition, episodic memory, language, and executive functions over a mean follow-up period of 8 years. SDC4 associations with cognition were mainly mediated by global tau-PET burden. Importantly, our pseudo-time models estimate that SDC4 upregulation begins very early in AD pathogenesis near the point of amyloid-positivity and increases more robustly following the point of tau-positivity. In our cohort, SDC4 was among the top 10 most important proteins (of >5,000 examined proteins) in predicting the pseudo-time models of AD progression and predicted these models to a potentially better extent than established AD biomarkers. Interpretation: Findings from this large translational longitudinal study suggest close associations of SDC4 upregulation with the progression of brain amyloid and tau pathologies in AD including the early preclinical stages. Further, we here demonstrate the ability of early increases in CSF SDC4 levels to predict trajectories of future cognitive decline over a mean follow-up period of 8 years. Therefore, we propose that SDC4 upregulation, as a potential surrogate of brain endothelial dysfunction, is an early event in AD pathogenesis which can reliably predict cognitive and pathological disease trajectories.


  • Open Access

    Analyzing heterogeneity in Alzheimer disease using multimodal normative modeling on imaging‐based ATN biomarkers

    by Sayantan Kumar, Tom Earnest, Braden Yang, Deydeep Kothapalli, Andrew J. Aschenbrenner, Jason Hassenstab, Chengie Xiong, Beau Ances, John Morris, Tammie L. S. Benzinger, et al.

    INTRODUCTION: Previous studies have applied normative modeling on a single neuroimaging modality to investigate Alzheimer disease (AD) heterogeneity. We employed a deep learning‐based multimodal normative framework to analyze individual‐level variation across ATN (amyloid‐tau‐neurodegeneration) imaging biomarkers. METHODS: We selected cross‐sectional discovery ( n = 665) and replication cohorts ( n = 430) with available T1‐weighted magnetic resonance imaging (MRI), amyloid, and tau positron emission tomography (PET). Normative modeling estimated individual‐level abnormal deviations in amyloid‐positive individuals compared to amyloid‐negative controls. Regional abnormality patterns were mapped at different clinical group levels to assess intra‐group heterogeneity. An individual‐level disease severity index (DSI) was calculated using both the spatial extent and magnitude of abnormal deviations across ATN. RESULTS: Greater intra‐group heterogeneity in ATN abnormality patterns was observed in more severe clinical stages of AD. Higher DSI was associated with worse cognitive function and increased risk of disease progression. DISCUSSION: Subject‐specific abnormality maps across ATN reveal the heterogeneous impact of AD on the brain. Highlights: Normative modeling examined AD heterogeneity across multimodal imaging biomarkers. Heterogeneity in spatial patterns of gray matter atrophy, amyloid, and tau burden. Higher within‐group heterogeneity for AD patients at advanced dementia stages. Patient‐specific metric summarized extent of neurodegeneration and neuropathology. Metric is a marker of poor brain health and can monitor risk of disease progression.


    • 15 April 2025
      • Vol. 21  (4)
    Open Access

    Analyzing heterogeneity in Alzheimer disease using multimodal normative modeling on imaging‐based ATN biomarkers

    by Sayantan Kumar, Tom Earnest, Braden Yang, Deydeep Kothapalli, Andrew J. Aschenbrenner, Jason Hassenstab, Chengie Xiong, Beau Ances, John Morris, Tammie L. S. Benzinger, et al.

    Previous studies have applied normative modeling on a single neuroimaging modality to investigate Alzheimer disease (AD) heterogeneity. We employed a deep learning‐based multimodal normative framework to analyze individual‐level variation across ATN (amyloid‐tau‐neurodegeneration) imaging biomarkers. We selected cross‐sectional discovery (n = 665) and replication cohorts (n = 430) with available T1‐weighted magnetic resonance imaging (MRI), amyloid, and tau positron emission tomography (PET). Normative modeling estimated individual‐level abnormal deviations in amyloid‐positive individuals compared to amyloid‐negative controls. Regional abnormality patterns were mapped at different clinical group levels to assess intra‐group heterogeneity. An individual‐level disease severity index (DSI) was calculated using both the spatial extent and magnitude of abnormal deviations across ATN. Greater intra‐group heterogeneity in ATN abnormality patterns was observed in more severe clinical stages of AD. Higher DSI was associated with worse cognitive function and increased risk of disease progression. Subject‐specific abnormality maps across ATN reveal the heterogeneous impact of AD on the brain. Normative modeling examined AD heterogeneity across multimodal imaging biomarkers. Heterogeneity in spatial patterns of gray matter atrophy, amyloid, and tau burden. Higher within‐group heterogeneity for AD patients at advanced dementia stages. Patient‐specific metric summarized extent of neurodegeneration and neuropathology. Metric is a marker of poor brain health and can monitor risk of disease progression.